E Grilli

Publications (6)11.28 Total impact

• Source

  Available from: cnrs.fr

  Article: Rifampicin combined regimens for gram-negative infections: data from the literature.

  C M J Drapeau, E Grilli, N Petrosillo
  [show abstract] [hide abstract]
  ABSTRACT: Multidrug-resistant (MDR) gram-negative bacterial infections are associated with high morbidity and mortality. Given the lack of availability of new highly effective antimicrobial drugs against multiresistant strains, combination regimens are administered that include rifampicin for its demonstrated in vitro synergism with multiple drugs. A literature review was performed of clinical studies reporting the use of rifampicin in the treatment of MDR gram-negative bacterial infections. Nineteen studies were found, including only one randomised controlled study. Data in the literature on combined therapeutic regimens with rifampicin are limited and refer mostly to uncontrolled studies. Therefore, the real clinical benefit of using rifampicin-containing therapies for the treatment of gram-negative multiresistant bacteria in terms of clinical outcome and survival rates still needs to be assessed.
  International journal of antimicrobial agents 10/2009; 35(1):39-44. · 3.03 Impact Factor
• Article: The novel influenza A (H1N1) virus pandemic: An update.

  N Petrosillo, S Di Bella, C M Drapeau, E Grilli
  [show abstract] [hide abstract]
  ABSTRACT: In the 4 months since it was first recognized, the pandemic strain of a novel influenza A (H1N1) virus has spread to all continents and, after documentation of human-to-human transmission of the virus in at least three countries in two separate World Health Organization (WHO) regions, the pandemic alert was raised to level 6. The agent responsible for this pandemic, a swine-origin influenza A (H1N1) virus (S-OIV), is characterized by a unique combination of gene segments that has not previously been identified among human or swine influenza A viruses. As of 31th July 2009, 168 countries and overseas territories/communities have each reported at least one laboratory-confirmed case of pandemic H1N1 infection. There have been a total of 162,380 reported cases and 1154 associated deaths. Influenza epidemics usually take off in autumn, and it is important to prepare for an earlier start this season. Estimates from Europe indicate that 230 millions Europe inhabitants will have clinical signs and symptoms of S-OIV this autumn, and 7- 35% of the clinical cases will have a fatal outcome, which means that there will be 160,000- 750,000 H1N1-related deaths. A vaccine against H1N1 is expected to be the most effective tool for controlling influenza A (H1N1) infection in terms of reducing morbidity and mortality and limiting diffusion. However, there are several issues with regard to vaccine manufacture and approval, as well as production capacity, that remain unsettled. We searched the literature indexed in PubMed as well as the websites of major international health agencies to obtain the material presented in this update on the current S-OIV pandemic.
  Annals of thoracic medicine. 10/2009; 4(4):163-72.
• Article: An adult HIV patient with unilateral Moyamoya syndrome.

  V Galati, E Grilli, F Sallustio, N Petrosillo
  [show abstract] [hide abstract]
  ABSTRACT: Moyamoya disease is a rare idiopathic neurological disorder due to occlusion of the circle of Willis. "Moyamoya syndrome", a radiographic picture resembling Moyamoya disease, is associated with systemic diseases. Only two cases of moyamoya syndrome in adults with advanced HIV disease and a single case in a child have been reported until now. We describe a case of unilateral Moyamoya syndrome in a patient with well-controlled HIV infection.
  Clinical neurology and neurosurgery 09/2009; 112(1):76-8. · 1.30 Impact Factor
• Article: The novel influenza A (H1N1) virus pandemic: An update

  N Petrosillo, Di Bella S, C Drapeau, E Grilli
  [show abstract] [hide abstract]
  ABSTRACT: In the 4 months since it was first recognized, the pandemic strain of a novel influenza A (H1N1) virus has spread to all continents and, after documentation of human-to-human transmission of the virus in at least three countries in two separate World Health Organization (WHO) regions, the pandemic alert was raised to level 6. The agent responsible for this pandemic, a swine-origin influenza A (H1N1) virus (S-OIV), is characterized by a unique combination of gene segments that has not previously been identified among human or swine influenza A viruses. As of 31th July 2009, 168 countries and overseas territories/communities have each reported at least one laboratory-confirmed case of pandemic H1N1 infection. There have been a total of 162,380 reported cases and 1154 associated deaths. Influenza epidemics usually take off in autumn, and it is important to prepare for an earlier start this season. Estimates from Europe indicate that 230 millions Europe inhabitants will have clinical signs and symptoms of S-OIV this autumn, and 7– 35% of the clinical cases will have a fatal outcome, which means that there will be 160,000– 750,000 H1N1-related deaths. A vaccine against H1N1 is expected to be the most effective tool for controlling influenza A (H1N1) infection in terms of reducing morbidity and mortality and limiting diffusion. However, there are several issues with regard to vaccine manufacture and approval, as well as production capacity, that remain unsettled. We searched the literature indexed in PubMed as well as the websites of major international health agencies to obtain the material presented in this update on the current S-OIV pandemic.
  Annals of Thoracic Medicine. 01/2009;
• Article: Cerebral tubercular lesions in a patient treated with Infliximab for Crohn’s disease

  V. Galati, E. Grilli, E. Busi Rizzi, C. Prantera, N. Petrosillo
  Journal of Neurology 11/2008; 255(12):1981-1982. · 3.47 Impact Factor
• Article: Cerebral tubercular lesions in a patient treated with infliximab for Crohn's disease.

  V Galati, E Grilli, E Busi Rizzi, C Prantera, N Petrosillo
  Journal of Neurology 11/2008; 255(12):1981-2. · 3.47 Impact Factor